165 filings
Page 3 of 9
S-8
ql5uq5rb
14 Jan 22
Registration of securities for employees
5:04pm
8-K
sday3abg6ydqrmixo
21 Dec 21
PhaseBio Provides Pemziviptadil (PB1046) Program Update
8:03am
8-K
jtiv ynoirtwbmd4gdt0
15 Nov 21
Regulation FD Disclosure
11:32am
424B5
3y1kvn7 03pcgdlawo
12 Nov 21
Prospectus supplement for primary offering
4:09pm
8-K
ppjbley
10 Nov 21
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
4:35pm
8-K
1irvkphct2tbyfo7z9h
3 Nov 21
PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab
8:04am
8-K
tsv0rlc
15 Sep 21
PhaseBio Appoints William D. Humphries to Board of Directors
8:04am
8-K
43uy96bisbur
12 Aug 21
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
10:11am
8-K
mwetde0 f2
10 Aug 21
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
8:03am
8-K
mbvq5 uwrjujic
17 Jun 21
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
8:13am
8-K
f1jkjgtt
4 Jun 21
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
nte7f0fk
13 May 21
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
4:06pm
8-K
ldlfzjj
19 Mar 21
PhaseBio Announces Pricing of Public Offering of Common Stock
4:08pm
424B5
mc1z6lw op
19 Mar 21
Prospectus supplement for primary offering
4:04pm
424B5
nategou0 6zr
17 Mar 21
Prospectus supplement for primary offering
5:07pm
S-8
rw52ti4f3qdfe
15 Mar 21
Registration of securities for employees
8:42am